The Oncologist, Vol. 6, No. 5, 415-427,
October 2001
© 2001 AlphaMed Press
Matrix Metalloproteinase Inhibitors: Current Developments and Future Perspectives
R. Hoekstra,
F.A.L.M. Eskens,
J. Verweij
Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital, Rotterdam, The Netherlands
Correspondence:
Ronald Hoekstra, M.D., Department of Medical Oncology, University Hospital Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. Fax: 31-10-463-4627; e-mail: hoekstra{at}oncd.azr.nl
Malignant tumors are characterized by invasive growth and metastasis. To facilitate this invasive behavior, the enzymatic breakdown of the extracellular matrix (ECM) is a prerequisite. Many human tumors are characterized by locally increased concentrations of matrix metalloproteinases (MMPs), enzymes that are able to degrade this ECM. A vast number of matrix metalloproteinase inhibitors (MMPIs) have been developed in recent years and after extensive preclinical testing, the results of the first clinical studies with several of these compounds have recently been presented. In this review we will describe some of the basic concepts of the degradation of the ECM, with special emphasis on the role of MMPs in the progression of cancer. Furthermore we will review the results of preclinical and clinical studies with MMPIs and discuss their future perspective.
Key Words. Matrix metalloproteinases • Matrix metalloproteinase inhibitors • Cancer • Clinical studies
This article has been cited by other articles:

|
 |

|
 |
 
J. P.G. Sluijter, D. P.V. de Kleijn, and G. Pasterkamp
Vascular remodeling and protease inhibition-bench to bedside
Cardiovasc Res,
February 15, 2006;
69(3):
595 - 603.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Vanhoutte, M. Schellings, Y. Pinto, and S. Heymans
Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: A temporal and spatial window
Cardiovasc Res,
February 15, 2006;
69(3):
604 - 613.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. C. Miner and W. L. Miller
A Look Between the Cardiomyocytes: The Extracellular Matrix in Heart Failure
Mayo Clin. Proc.,
January 1, 2006;
81(1):
71 - 76.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Guignabert, L. Taysse, J.-H. Calvet, E. Planus, S. Delamanche, S. Galiacy, and M.-P. d'Ortho
Effect of doxycycline on sulfur mustard-induced respiratory lesions in guinea pigs
Am J Physiol Lung Cell Mol Physiol,
July 1, 2005;
289(1):
L67 - L74.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. KJAeR
Role of Extracellular Matrix in Adaptation of Tendon and Skeletal Muscle to Mechanical Loading
Physiol Rev,
April 1, 2004;
84(2):
649 - 698.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. M. Yarbrough, R. Mukherjee, G. P. Escobar, J. T. Mingoia, J. A. Sample, J. W. Hendrick, K. B. Dowdy, J. E. McLean, A. S. Lowry, T. P. O'Neill, et al.
Selective Targeting and Timing of Matrix Metalloproteinase Inhibition in Post-Myocardial Infarction Remodeling
Circulation,
October 7, 2003;
108(14):
1753 - 1759.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. van der Pluijm, M. Deckers, B. Sijmons, H. de Groot, J. Bird, R. Wills, S. Papapoulos, A. Baxter, and C. Lowik
In Vitro and in Vivo Endochondral Bone Formation Models Allow Identification of Anti-Angiogenic Compounds
Am. J. Pathol.,
July 1, 2003;
163(1):
157 - 163.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B.-K. Choi, H. J. Lee, J. H. Kang, G. J. Jeong, C. K. Min, and Y.-J. Yoo
Induction of Osteoclastogenesis and Matrix Metalloproteinase Expression by the Lipooligosaccharide of Treponema denticola
Infect. Immun.,
January 1, 2003;
71(1):
226 - 233.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by AlphaMed Press.
|
|